Exact Sciences Corporation (NASDAQ:EXAS) kept active in under and overvalue discussion, EXAS holds price to book ratio of 5.20 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.
Exact Sciences (EXAS) stock soared Monday after the maker of the Cologuard DNA screening test for colon cancer pre-reported a solid Q4 income beat, saying Cologuard procedures in 2016 more than doubled. Canaccord Genuity analyst Mark Massaro called the results excellent and reiterated his buy rating and 24 price target on Exact Sciences stock. Massaro said the company’s Q4 patient compliance rate of 67%, flat with Q3, “is encouraging to us given that this bucks the trend of recent quarterly declines.” He had been expecting a 65% compliance rate, which is the number of valid test results reported divided by the number of collection kits shipped to patients.
The co is presenting price to cash flow as 5.80, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 7.45% for a week and 4.95% for a month. Its beta stands at 0.79 times. Narrow down four to firm performance, its weekly performance was 34.58% and monthly performance was 25.65%.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) runs in leading trade, it are rising 0.65% to traded at $48.14. IONS attain analyst recommendation of 2.70 on scale of 1-5 with week’s performance of 0.65%. Ionis Pharmaceuticals, Inc. (IONS) reported that the Company expects to importantly improve upon its 2016 financial guidance. Ionis expects to end 2016 with pro forma net operating income in the low to mid $20 million range and more than $650 million in cash.
“2016 was marked by major regulatory and development achievements with SPINRAZA and the continued success in advancing our pipeline of drugs to treat both rare and more prevalent diseases across multiple therapeutic areas. In 2016, we generated more than $340 million in revenue, including more than $150 million in the fourth quarter,” said Elizabeth L. Hougen, chief financial officer at Ionis Pharmaceuticals.
To find out the technical position of IONS, it holds price to book ratio of 41.86 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. IONS is presenting price to cash flow of 8.35.
EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -122.60%, and looking further price to next year’s EPS is 20.20%. While take a short look on price to sales ratio, that was 24.49.